Alumis eyes $300 million in proceeds in IPO

California-based biopharmaceutical company plans to trade on the Nasdaq under the symbol ALMS.

Previous post The S&P 500 is headed for 15,000 by the end of the decade, says Tom Lee, who foresaw the 2023 rally
Next post Tether announces cease of USDT minting on Algorand and EOS